Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations with laboratory findings, comorbidities, and medications

İsmail ERTÜRK; Erdim SERTOĞLU; Fatih YEŞİLDAL; Ramazan ACAR; Taner ÖZGÜRTAŞ; Kenan SAĞLAM

Makale detayları

Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations with laboratory findings, comorbidities, and medications

Yazarlar:

İsmail ERTÜRK | Erdim SERTOĞLU | Fatih YEŞİLDAL | Ramazan ACAR | Taner ÖZGÜRTAŞ | Kenan SAĞLAM

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1192-1199

Belge Tipi:

Makale

Yayın Tarihi:

12/2018

Belge Dili:

İngilizce

Document ID (Org No.):

2000750464

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Özet:

 


                        Background/aim:
  The  clinical  effect  of  angiostatin  in  diabetes  mellitus  (DM)  patients  receiving  insulin  is  a  meaningful  gap  in  the  
literature. In this study, we aimed to show the levels and the clinical significance of angiostatin in DM patients receiving insulin.
Materials and methods:
 This is a case-control study. Serum angiostatin levels were determined by ELISA. A total of 83 people consisting 
of healthy subjects (n = 36) and patients with a diagnosis of DM receiving insulin therapy (n = 47) were included in this study.
Results:
  The  mean  angiostatin  levels  of  the  DM  group  were  significantly  higher  than  those  of  the  control  group  (86.0  ±  68.1  ng/mL  
and 58.0 ± 22.4 ng/mL, respectively; P = 0.011). Significantly lower angiostatin levels were determined in the DM patients receiving 
metformin with respect to those not receiving metformin (97.2 ± 74.4 ng/mL and 49.3 ± 7.0 ng/mL, respectively; P = 0.021). Significantly 
higher levels of angiostatin were observed among the DM patients using a beta-blocker (BB) than the DM patients not using a BB (115.5 
± 78.71 ng/mL and 73.44 ± 60.08 ng/mL, respectively; p = 0.029).
Conclusion: 
This is the first study evaluating and demonstrating the serum angiostatin levels in DM patients receiving insulin. Further 
studies are required to understand the effect of angiostatin in diabetics and the effect of medications on angiogenesis in these patients.
                    

.

Makale detayları

Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations with laboratory findings, comorbidities, and medications

Yazarlar: İsmail ERTÜRK | Erdim SERTOĞLU | Fatih YEŞİLDAL | Ramazan ACAR | Taner ÖZGÜRTAŞ | Kenan SAĞLAM

Yayıncı: TUBITAK

Ana Başlıklar: Sağlık teşvikleri

Dergi: Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1192-1199

Belge Tipi: Makale

Yayın Tarihi: 12/2018

Belge Dili: İngilizce

Document ID (Org No.): 2000750464

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

Sayı

Yazarlar:

İsmail ERTÜRK | Erdim SERTOĞLU | Fatih YEŞİLDAL | Ramazan ACAR | Taner ÖZGÜRTAŞ | Kenan SAĞLAM

Yayıncı:

TUBITAK

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 6, pp.1192-1199

Belge Tipi:

Makale

Yayın Tarihi:

12/2018

Belge Dili:

İngilizce

Document ID (Org No.):

2000750464

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144